These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 33502090)

  • 21. Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease.
    Filippatos G; Anker SD; Pitt B; McGuire DK; Rossing P; Ruilope LM; Butler J; Jankowska EA; Michos ED; Farmakis D; Farjat AE; Kolkhof P; Scalise A; Joseph A; Bakris GL; Agarwal R
    Eur Heart J Cardiovasc Pharmacother; 2022 Dec; 9(1):85-93. PubMed ID: 36251465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kidney and heart failure events are bidirectionally associated in patients with type 2 diabetes and cardiovascular disease.
    Sharma A; Inzucchi SE; Testani JM; Ofstad AP; Fitchett D; Mattheus M; Verma S; Zannad F; Wanner C; Kraus BJ
    ESC Heart Fail; 2024 Apr; 11(2):737-747. PubMed ID: 38155446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
    McGuire DK; Van de Werf F; Armstrong PW; Standl E; Koglin J; Green JB; Bethel MA; Cornel JH; Lopes RD; Halvorsen S; Ambrosio G; Buse JB; Josse RG; Lachin JM; Pencina MJ; Garg J; Lokhnygina Y; Holman RR; Peterson ED;
    JAMA Cardiol; 2016 May; 1(2):126-35. PubMed ID: 27437883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
    Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S
    Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease　- Results From EMPA-REG OUTCOME
    Kaku K; Lee J; Mattheus M; Kaspers S; George J; Woerle HJ;
    Circ J; 2017 Jan; 81(2):227-234. PubMed ID: 28025462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetes.
    Krämer BK; Hauske SJ; Chilton R; Mann JFE; Gullestad L; Fitchett D; Mattheus M; Steubl D; Wanner C
    J Diabetes Complications; 2023 Sep; 37(9):108588. PubMed ID: 37633072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
    Ferreira JP; Fitchett D; Ofstad AP; Kraus BJ; Wanner C; Zwiener I; Zinman B; Lauer S; George JT; Rossignol P; Zannad F
    Am J Hypertens; 2020 Dec; 33(12):1092-1101. PubMed ID: 32369546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?
    Inzucchi SE; Fitchett D; Jurišić-Eržen D; Woo V; Hantel S; Janista C; Kaspers S; George JT; Zinman B;
    Diabetes Obes Metab; 2020 Apr; 22(4):631-639. PubMed ID: 31789445
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME.
    Böhm M; Fitchett D; Ofstad AP; Brueckmann M; Kaspers S; George JT; Zwiener I; Zinman B; Wanner C; Marx N; Mancia G; Anker SD; Mahfoud F
    J Hypertens; 2020 Sep; 38(9):1829-1840. PubMed ID: 32618884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Oyama K; Raz I; Cahn A; Goodrich EL; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson IAM; Mosenzon O; Sabatine MS; Wiviott SD
    JAMA Cardiol; 2022 Sep; 7(9):914-923. PubMed ID: 35857296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA-REG OUTCOME trial with a focus on Asia.
    Ji Q; Ji L; Mu Y; Zhao J; Zinman B; Wanner C; George JT; Zwiener I; Ueki K; Yokote K; Ogawa W; Johansen OE
    Diabetes Obes Metab; 2021 Aug; 23(8):1886-1891. PubMed ID: 33950573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.
    Filippatos G; Anker SD; Agarwal R; Ruilope LM; Rossing P; Bakris GL; Tasto C; Joseph A; Kolkhof P; Lage A; Pitt B;
    Circulation; 2022 Feb; 145(6):437-447. PubMed ID: 34775784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence of Hospitalization for Heart Failure Relative to Major Atherosclerotic Events in Type 2 Diabetes: A Meta-analysis of Cardiovascular Outcomes Trials.
    Sacre JW; Magliano DJ; Shaw JE
    Diabetes Care; 2020 Oct; 43(10):2614-2623. PubMed ID: 32958618
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
    Ferreira JP; Kraus BJ; Zwiener I; Lauer S; Zinman B; Fitchett DH; Koitka-Weber A; George JT; Ofstad AP; Wanner C; Zannad F
    J Am Heart Assoc; 2021 Apr; 10(7):e020053. PubMed ID: 33754809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria.
    Sarraju A; Bakris G; Cannon CP; Cherney D; Damaraju CV; Figtree GA; Gogate J; Greene T; Heerspink HJL; Januzzi JL; Neal B; Jardine MJ; Blais J; Kosiborod M; Levin A; Lingvay I; Weir MR; Perkovic V; Mahaffey KW
    J Am Coll Cardiol; 2022 Nov; 80(18):1721-1731. PubMed ID: 36302584
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium-glucose cotransporter-2 inhibitor ertugliflozin.
    Corbin KD; Dagogo-Jack S; Cannon CP; Cherney DZI; Cosentino F; Frederich R; Liu J; Pong A; Lin J; Cater NB; Pratley RE
    Diabetes Obes Metab; 2023 Mar; 25(3):758-766. PubMed ID: 36394384
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME
    Langslet G; Zinman B; Wanner C; Hantel S; Espadero RM; Fitchett D; Johansen OE
    Diab Vasc Dis Res; 2020; 17(6):1479164120975256. PubMed ID: 33307785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short-Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
    Waijer SW; Xie D; Inzucchi SE; Zinman B; Koitka-Weber A; Mattheus M; von Eynatten M; Inker LA; Wanner C; Heerspink HJL
    J Am Heart Assoc; 2020 Sep; 9(18):e016976. PubMed ID: 32893717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?
    Coleman RL; Gray AM; Broedl Md UC; Fitchett D; George JT; Woerle HJ; Zinman B; Holman RR
    Diabetes Obes Metab; 2020 Jul; 22(7):1151-1156. PubMed ID: 32115840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCEL trial.
    Samsky MD; Mentz RJ; Stebbins A; Lokhnygina Y; Aday AW; Pagidipati NJ; Jones WS; Katona BG; Patel MR; Holman RR; Hernandez AF; Gutierrez JA
    Atherosclerosis; 2021 Dec; 338():1-6. PubMed ID: 34741929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.